Cargando…

PB1789: WT1, HMGA2, EVI1, BAALC AND PRAME MRNA LEVELS IN PATIENTS BLOOD SAMPLES WITH ACUTE LEUKEMIA

Detalles Bibliográficos
Autores principales:	Stolyar, M., Gorbenko, A., Olkhovskiy, I., Mikhalev, M., Bakhtina, V., Kaporskaya, T., Lyskova, V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428965/ http://dx.doi.org/10.1097/01.HS9.0000850008.94896.09

Ejemplares similares

PB2176: MRNA OF MPL AND JAK2 GENES IN PLATELETS IS ASSOCIATED WITH THEIR ASPIRIN RESISTANCE IN MPN PATIENTS
por: Stolyar, Marina, et al.
Publicado: (2023)

PB1804: CLINICAL AND DEMOGRAFIC RELATIONS OF BAALC GENE OVEREXPRESSION IN AML PATIENTS - A SINGLE-CENTER OBSERVATIONS
por: Aleksov, E., et al.
Publicado: (2022)

A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC
por: Brand, Jaap, et al.
Publicado: (2013)

WT-1, BAALC, and ERG Expressions in Iranian Patients with Acute Myeloid Leukemia Pre- and Post-chemotherapy
por: Mehralizadeh, Hossein, et al.
Publicado: (2021)

PB1789: RAC1 INHIBITION IS FEASIBLE AND AFFECTS CELL MIGRATION IN A ZEBRAFISH LARVAE MODEL OF AML, INVESTIGATED USING A SOFTWARE TOOL FOR SINGLE-CELL VISUALIZATION
por: Hemsing, Anette Lodvir, et al.
Publicado: (2023)

PB2061: A RARE CASE OF CALR MUTATION IN JAK2-NEGATIVE PATIENT WITH POLYCYTHEMIA
por: Subbotina, T., et al.
Publicado: (2022)

Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Development of cellular and humoral response against WT1 protein vaccination in mice
por: Nicoli, Paolo, et al.
Publicado: (2015)

Priming of PRAME- and WT1-specific CD8(+) T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy
por: van den Ancker, Willemijn, et al.
Publicado: (2013)

PB2066: THE STUDY OF GSTP1 AND MDR1 GENES POLYMORPHISMS IN HODGKIN’S LYMPHOMA AND THEIR LINK WITH CHEMOTHERAPY RESPONSE.
por: Voytko, M., et al.
Publicado: (2022)

PB2503: MODULATION OF ERYTHROCYTE FUNCTION BY ENDOTHELIN-1
por: Teixeira-Alves, Lyzes Rosa, et al.
Publicado: (2023)

PB2351: ANXIETY AT THE HEMATOLOGIST
por: Trojan, S., et al.
Publicado: (2022)

PB2485: INVESTIGATING THE EXPRESSION OF MUCIN-1 (MUC-1) DURING ERYTHROID DIFFERENTIATION
por: Hassan, Hammad, et al.
Publicado: (2023)

Preferentially Expressed Antigen of Melanoma (PRAME) and Wilms’ Tumor 1 (WT 1) Genes Expression in Childhood Acute Lymphoblastic Leukemia, Prognostic Role and Correlation with Survival
por: Khateeb, Engy El, et al.
Publicado: (2014)

PB2008: CUTANEOUS HEMORRHAGIC SYNDROME IN PATIENTS WITH AL-AMYLOIDOSIS
por: Khyshova, V., et al.
Publicado: (2022)

PB2086: CHRONIC LYMPHOPROLIFERATIVE DISORDER OF NK CELLS WITH LIVER INFILTRATION
por: Otasevic, V., et al.
Publicado: (2022)

PB2172: PREVALENCE OF FIP1L1-PDGFRΑ FUSION IN TUNISIAN PATIENTS WITH HYPEREOSINOPHILIA
por: Torkhani, Nermine, et al.
Publicado: (2023)

EVI1 in Leukemia and Solid Tumors
por: Liang, Beiyuan, et al.
Publicado: (2020)

PB2344: RESILIENCE IN PATIENTS WITH LYMPHOID MALIGNANCIES: THE REPLY STUDY.
por: Dos Santos, G., et al.
Publicado: (2022)

PB2303: THROMBOCYTOPENIA IN COVID-19 PATIENTS ON ECMO SUPPORT
por: Jones, C., et al.
Publicado: (2022)

PB2162: INCREASED OXIDATIVE STRESS IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Antic, D., et al.
Publicado: (2022)

PB2166: TET ENZYMES PROTECT AGAINST FATAL LYMPHOPROLIFERATION
por: Spoeck, S., et al.
Publicado: (2022)

PB1966: HEMOPOIETIC NICHE IMPAIRMENT IN TREATED MULTIPLE MYELOMA PATIENTS
por: Semenova, N. Y., et al.
Publicado: (2022)

PB2350: SAFETY AND EFFICACY OF HYPODERMOCLYSIS IN PATIENTS WITH HEMATOLOGICAL CANCERS
por: Kodru, A., et al.
Publicado: (2022)

PB1968: EPIGENETIC AND GENETIC INVESTIGATION OF SOCS-1 GENE IN PATIENTS WITH MULTIPLE MYELOMA
por: Serin, I., et al.
Publicado: (2022)

PB2080: LOW DUP1 EXPRESSION PREDICTS POOR PROGNOSIS IN MULTIPLE MYELOMA
por: Lu, Jinfeng, et al.
Publicado: (2023)

PB2383: MICROSATELLITE INSTABILITY AND 9P24.1 ALTERATIONS IN HODGKIN LYMPHOMA
por: Tregubova, Ekaterina, et al.
Publicado: (2023)

PB2006: MOLECULAR CLINICAL CHARACTERISTICS AND PROGNOSIS OF MDS PATIENTS WITH RUNX1 MUTATION
por: Huang, Nanfang, et al.
Publicado: (2023)

PB1916: SOMATIC MUTATIONS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME IN RUSSIAN PATIENTS
por: Kohno, A., et al.
Publicado: (2022)

PB1908: COVID-19 INSIGHTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DIAGNOSIS AND TREATMENT
por: Musteata, V.
Publicado: (2022)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
por: Van Oorschot, V., et al.
Publicado: (2022)

PRAME protein expression in DICER1‐related tumours
por: Thorner, Paul S, et al.
Publicado: (2022)

PRAME protein expression in DICER1‐related tumours
por: Thorner, Paul S, et al.
Publicado: (2022)

PB1790: ABCB1 AS A POTENTIAL BENEFICIAL TARGET OF MIDOSTAURIN IN ACUTE MYELOID LEUKEMIA
por: Sucha, S., et al.
Publicado: (2022)

PB1803: SMAD1 IS A TUMOR SUPPRESSOR IN ACUTE MYELOID LEUKEMIA WITH MLL REARRANGEMENT
por: Dietsche, Lisa, et al.
Publicado: (2023)

PB1917: EXPRESSION OF THE LONG NON-CODING RNA MALAT1 IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Karan-Đurašević, Teodora, et al.
Publicado: (2023)

PB1808: EPIGENETIC INHIBITOR SCREEN TO IDENTIFY THERAPEUTIC CANDIDATES FOR MNX1-OVEREXPRESSING AML
por: Kelekci, Simge, et al.
Publicado: (2023)

PB1880: ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1 – A DIFFERENT ENTITY IN THE ELDERLY?
por: Gomes, Rita S, et al.
Publicado: (2023)

PB1797: THE PROGNOSTIC SIGNIFICANCE OF BCAT1 ON NPM1+FLT3-ITD+ AML PATIENTS AND RELATED MOLECULAR MECHANISMS
por: Pan, Xinan, et al.
Publicado: (2023)

PB2187: VIABILITY AND PROLIFERATIVE POTENTIAL OF AUTOGRAFT HEMATOPOIETIC STEM CELLS
por: Balashova, V., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qq7m3n2v881bs5enp4lcucocv8